RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cabaletta Bio Stock

Cabaletta Bio Dividend 2024

Cabaletta Bio Dividend

0 USD

Cabaletta Bio Dividend yield

Ticker

CABA

ISIN

US12674W1099

WKN

A2PTTB

How much dividend does Cabaletta Bio 2024 pay?

According to the latest status from November 2024, Cabaletta Bio paid a total of 0 USD per share in dividends within the last 12 months. With the current Cabaletta Bio price of 4.49 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Cabaletta Bio Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Cabaletta Bio Dividend Safe?

Cabaletta Bio has been increasing the dividend for 0 years.

Over the past 7 years, Cabaletta Bio has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Cabaletta Bio's Dividend Distributions

Cabaletta Bio’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Cabaletta Bio's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Cabaletta Bio's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Cabaletta Bio’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Cabaletta Bio Aktienanalyse

What does Cabaletta Bio do?

Cabaletta Bio Inc is a biotech company founded in 2017, based in Philadelphia, Pennsylvania. The founders of the company are Michael Milone and Aimee Payne, both renowned experts in immunology. The business model of Cabaletta Bio Inc is to treat rare diseases using T-cell therapies. T-cell therapy is a form of immunotherapy where the patient's own T-cells, which have been taken from their blood, are genetically modified and then reintroduced to the patient. This process is intended to enable the patient's T-cells to recognize and fight specific diseased cells. Cabaletta Bio Inc focuses on developing therapies for rare autoimmune diseases and difficult-to-treat cancers. The company specializes in the development of CAR-T cell therapies (CAR-T stands for Chimeric Antigen Receptor) that enable the patient's T-cells to attack specific tumor or autoimmune cells in the body. Novel CAR-T cell technologies have been developed to allow the T-cells to recognize disease-specific antigens on cell surfaces. This way, the T-cells can selectively target and destroy diseased cells. Cabaletta Bio Inc is working on various areas of T-cell therapy development. The first area involves developing therapies for rare autoimmune diseases such as systemic scleroderma, Juvenile syndrome, or pemphigus vulgaris. The company has initiated clinical trials and collaborates with other research institutions and companies to advance the development of CAR-T cell therapies. Another area of focus for Cabaletta Bio Inc is treating cancers that are difficult to treat and lack therapeutic options, such as leukemia, solid tumors, or sarcomas. Identifying and targeting specific cells for these types of cancers is particularly challenging. Therefore, the company is actively working to develop novel CAR-T cell technologies that enable the T-cells to recognize and combat diseased cells. Currently, Cabaletta Bio Inc does not offer any commercial products as it is still in the phase of clinical research and development. However, the company aims to advance the development of T-cell therapies and make its technology accessible to patients with rare and difficult-to-treat diseases. Overall, Cabaletta Bio Inc has received recognition and support from leading scientists and organizations in recent years. The company has received several awards and accolades for its work, including the New Frontier Award from the National Organization for Rare Disorders (NORD) and the Fast Track Award from the US Food and Drug Administration (FDA). Cabaletta Bio Inc collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. In summary, Cabaletta Bio Inc is an emerging biotech company specializing in the development of T-cell therapies. The company aims to treat rare and difficult-to-treat diseases and make its technology accessible to patients. Although the company currently does not offer commercial products, it has received recognition and support from leading scientists and organizations in recent years and collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. Cabaletta Bio is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Cabaletta Bio stock

How much dividend does Cabaletta Bio pay?

Over the past 12 months, Cabaletta Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cabaletta Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Cabaletta Bio?

The current dividend yield of Cabaletta Bio is .

When does Cabaletta Bio pay dividends?

Cabaletta Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cabaletta Bio?

Cabaletta Bio paid dividends every year for the past 0 years.

What is the dividend of Cabaletta Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cabaletta Bio located?

Cabaletta Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cabaletta Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cabaletta Bio from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Cabaletta Bio pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Cabaletta Bio in the year 2023?

In the year 2023, Cabaletta Bio distributed 0 USD as dividends.

In which currency does Cabaletta Bio pay out the dividend?

The dividends of Cabaletta Bio are distributed in USD.

Andere Kennzahlen von Cabaletta Bio

Our stock analysis for Cabaletta Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cabaletta Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.